黄素 - - 通过产药方法和新型配方提高生物可用性
Narsaiah Chelimela1, Rajasekhar Reddy Alavala2, Shobha Rani Satla1
1Centre for Pharmaceutical Sciences, Jawaharlal Nehru Technological University Hyderabad, Kukatpally, Hyderabad, 500085, India.
Chemistry & biodiversity
|February 24, 2024
概括
黄素是一种强大的天然化合物,具有较差的生物利用性. 本综述探讨了诸如结构修改和新型药物输送系统等策略,以增强黄素的作用.
科学领域:
- 药理学和制药科学 药理学和制药科学
- 自然产品化学 自然产品化学
- 药物输送系统 药物输送系统
背景情况:
- 黄素是一种具有多种治疗潜力的天然药理剂.
- 在临床应用中存在重大挑战,因为其生物可用性不佳,包括水溶性低,透性降低和快速消除.
- 克服这些药理动力学限制对于实现黄素的治疗益处至关重要.
研究的目的:
- 审查提高黄素药理学特性的策略.
- 探索黄素衍生物和改性配方的发展.
- 为改善黄素的治疗疗效提供见解,而不会影响其药理动力学.
主要方法:
- 通过与生物分子,聚合物,自然产品和金属离子的结合,开发黄素衍生物.
- 库尔库与天然代谢抑制剂的同时使用.
- 制备先进的药物输送系统,包括菌体,脂质体,纳米乳液,纳米颗粒和微凝.
主要成果:
- 各种结构修改和配方方法可以显著提高黄素的可溶性,透性,并减少其清除.
- 这些策略旨在提高黄素的药理动力学特征,同时保持其内在的药理动力学活性.
- 审查的方法为开发更有效的基于黄素的治疗方法提供了有希望的途径.
结论:
- 解决黄素的药理动力学挑战对于其成功的治疗应用至关重要.
- 结构修改和先进的药物输送系统是提高黄素生物可用性的关键策略.
- 本综述强调了这些方法的潜力,以释放黄素的全部治疗价值.
相关概念视频
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
Factors Influencing Bioavailability: First-Pass Elimination
6.4K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
6.4K
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
208
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
208
Biopharmaceutics and Pharmacokinetics: Overview
2.0K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.0K
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Factors Influencing Drug Absorption: Presystemic Elimination
219
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
219


